Media stories about TRACON Pharmaceuticals (NASDAQ:TCON) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TRACON Pharmaceuticals earned a news impact score of 0.06 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 48.5554072096128 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
TRACON Pharmaceuticals stock traded up $0.02 during trading hours on Friday, hitting $2.25. 138,299 shares of the stock were exchanged, compared to its average volume of 156,120. The company has a current ratio of 4.84, a quick ratio of 4.84 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $65.65 million, a price-to-earnings ratio of -1.97 and a beta of 1.87. TRACON Pharmaceuticals has a 12 month low of $1.90 and a 12 month high of $3.95.
TRACON Pharmaceuticals (NASDAQ:TCON) last issued its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.02). equities research analysts predict that TRACON Pharmaceuticals will post -1.23 EPS for the current year.
Several research analysts recently issued reports on TCON shares. ValuEngine raised shares of TRACON Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Zacks Investment Research raised shares of TRACON Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research note on Tuesday, August 14th.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD.
Recommended Story: Dividend Stocks – Are They Right For You?
Receive News & Ratings for TRACON Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.